Zhengming Jin

机构：Soochow University, First Affiliated Hospital of Soochow University · ORCID：0000-0003-1803-0008

发表论文 204 篇 · 总被引 2139 次 · h-index 21

代表论文

• Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults (2025 · Blood Advances · 被引 5)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results (2025 · Stroke · 被引 3)
• Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21). (2025 · Journal of Clinical Oncology · 被引 2)
• Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma (2024 · Blood · 被引 2)
• 61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL) (2025 · Hematological Oncology · 被引 1)